Needham analyst James Ricchiuti reiterates Coherent (NASDAQ:COHR) with a Buy and maintains $58 price target.
What 10 Analyst Ratings Have To Say About Allogene Therapeutics
Analysts have provided the following ratings for Allogene Therapeutics (NASDAQ:ALLO) within the last quarter: Bullish Somewhat Bullish Indifferent…